CD274 and neoplasm: Currently, there are three FDA-approved predictive biomarkers: Programmed cell death ligand-1 (PD-L1); microsatellite instability/defective mismatch repair (MSI/dMMR), and tumor mutational burden (TMB)), which are routinely used for patient selection for ICIs response in clinical practice.